Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.German biotech company ChromoTek has signed a license agreement with Bayer Pharma to use ChromoTek's proprietary Cell Cycle Chromobody Technology for drug profiling by High Content Analysis.
Subscribe to our email newsletter
According to the agreement, Bayer will apply Chromobody technology for real time monitoring of cell cycle progression in drug discovery.
The Chromobody Technology, a patented, universal live cell imaging technology, allows to trace endogenous intracellular antigens and to visualize dynamic changes of these targets within living cells.
The Cell Cycle Chromobody cell line licensed by Bayer traces the complete cell cycle in real time in live cells in a non-invasive manner while providing full flexibility to multiplex with other procedures.
ChromoTek R&D head Dr Kourosh Zolghadr said, "We are pleased to offer our customers efficient tools for achieving more detailed and physiologically relevant information on the effects of drug candidates on cell cycle progression."